Chang Tang Chang (born 1950), née Tang Nanshan (Chinese: 唐南珊; pinyin: Táng Nánshān), is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system.

In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies.

[1] Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.

Chang attended Taiwan's National Tsing Hua University, where she took undergraduate classes from future Nobel Prize winner Yuan T.

On the plane ride to the United States, Chang read James Watson’s book on the discovery of the double helix.

Tse Wen had an idea for treating allergies by blocking IgE (immunoglobulin E), and the Changs founded the biotechnology company Tanox.

Tse Wen continued his preferred work as a professor, and Chang served as president of the new company.

Tse Wen returned to Taiwan in 1996 to teach, while remained as a board member of Tanox until the company was acquired by Genentech.

[1] In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies.

[1][6] Chang is an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.

[6] During her career, Chang has received numerous academic, national and international awards for her leadership and contributions to the biopharmaceutical industry.

[5] In 2005, she was named a Most Respected Woman in Biotechnology (MedAd News, 2005), and also received the Global Business Achievement Hall of Fame Governor's Award from the Global Federation of Chinese Business Women in the Southern U.S.[1] In 2008 Chang was named to the Forbes Twenty-Five Notable Chinese Americans list.